Shared on18 Sep 25Fair value Increased 11%
Upward revisions in both expected revenue growth and net profit margin have driven analysts to raise Esprinet’s consensus price target from €6.17 to €6.83. Valuation Changes Summary of Valuation Changes for Esprinet The Consensus Analyst Price Target has significantly risen from €6.17 to €6.83.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 0.94%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Increased 3.95%
AnalystConsensusTarget has decreased revenue growth from 5.0% to 3.0% and decreased discount rate from 17.2% to 14.4%.